Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson's Program


Gain Therapeutics Inc GANX has presented new preclinical data from its Parkinson's Disease (PD) program at the 2022 Synuclein Meeting. 

  • The data show that the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase (GCase) protein, improves lysosomal health, and corrects abnormal phenotypes of PD.
  • The data also showed improved neuronal network connections and neuron survival.
  • Related: Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs.
  • The data were generated in two different in vitro models covering both WT and the two most pathogenic GBA1 mutations, L444P and N370S. 
  • Price Action: GANX shares surged 43.2% at $6.00 during the market session on the last check Tuesday.
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsParkinson’s DiseasePreclinical Phasewhy it's moving